FY2029 Earnings Estimate for ACRS Issued By Leerink Partnrs

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Aclaris Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the biotechnology company will post earnings of ($1.02) per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.86) per share.

A number of other research analysts also recently weighed in on the company. Piper Sandler raised Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $3.00 to $13.00 in a research note on Monday, November 18th. Jefferies Financial Group raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the company from $2.00 to $7.00 in a research note on Tuesday, November 19th. Leerink Partners upgraded Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. HC Wainwright raised Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Monday, December 23rd. Finally, BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $11.00.

Aclaris Therapeutics Price Performance

Shares of NASDAQ ACRS opened at $2.43 on Thursday. Aclaris Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $5.17. The firm has a market capitalization of $173.58 million, a P/E ratio of -4.67 and a beta of 0.50. The company’s 50 day simple moving average is $2.88 and its 200 day simple moving average is $2.05.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The business had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. bought a new stake in Aclaris Therapeutics in the 4th quarter valued at $82,000. Assenagon Asset Management S.A. acquired a new stake in shares of Aclaris Therapeutics in the 3rd quarter valued at about $214,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Aclaris Therapeutics by 187.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 216,826 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth about $383,000. Finally, Geode Capital Management LLC grew its holdings in shares of Aclaris Therapeutics by 9.3% during the third quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock worth $974,000 after buying an additional 72,309 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Insider Activity

In other Aclaris Therapeutics news, Director Anand Mehra bought 666,666 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $2.25 per share, with a total value of $1,499,998.50. Following the purchase, the director now owns 710,030 shares in the company, valued at $1,597,567.50. This trade represents a 1,537.37 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.40% of the stock is currently owned by company insiders.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.